Zi-Ming Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zi-Ming Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Kuo Zhang
CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing 100190, China
4 shared publications - Hao Wang
CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing, China
3 shared publications - Lei Wang
CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, China
3 shared publications - Ping-Ping He
CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST) No. 11 Beiyitiao, Zhongguancun, Beijing 100190, P. R. China
3 shared publications - Yu Fan
Hubei Key Laboratory of Catalysis and Materials Science, South-Central University for Nationalities, 182 Minzu Road, Hongshan District, Wuhan, Hubei 430074, People’s Republic of China
3 shared publications - Jiaqi Fan
CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China
2 shared publications
Latest Publications
- 1 August 2021
- Published by Elsevier in Biomaterials
- Vol. 275, 120900
An antibody-like peptidic network for anti-angiogenesis
- 1 August 2021
- Published by Elsevier in Biomaterials
- Vol. 275, 120900
An antibody-like peptidic network for anti-angiogenesis
- Open Access
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaaz4107
A biomimetic platelet based on assembling peptides initiates artificial coagulation
A biomimetic platelet based on assembling peptides initiates artificial coagulation for tumor therapy.
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaaz4107
Open AccessA biomimetic platelet based on assembling peptides initiates artificial coagulation
A biomimetic platelet based on assembling peptides initiates artificial coagulation for tumor therapy.
- 14 May 2020
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (6) , 7170-7180
Peptide-Based Nanoparticles Mimic Fibrillogenesis of Laminin in Tumor Vessels for Precise Embolization
Cancer therapeutic strategies based on angiogenesis attract great attention from fundamental and clinical research. Blocking oxygen and nutrition supply to tumor cells could inhibit the growth of tumor based on occlusion of blood vessels in tumor. Herein, we report a dual-responsive peptide-based nanoparticle, mimicking the laminin fibrillogenesis specifically and high-efficiently in tumor vessels, resulting in the blockage of tumor vessels and the growth inhibition of tumor. The laminin mimic peptide (LMMP) is designed with fibrillation sequence, pH-responsive sequence and targeting sequence. The LMMP in nanoformulation is delivered to the blood vessel in tumor, where the microenvironment (pH and microthrombus) enable LMMP to process laminin fibrillogenesis, constructing fibrous networks. The laminin-like fibrous networks capture red blood cells etc., forming occlusion specifically in tumor blood vessels for inhibiting the growth of tumor.
- 14 May 2020
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (6) , 7170-7180
Peptide-Based Nanoparticles Mimic Fibrillogenesis of Laminin in Tumor Vessels for Precise Embolization
Cancer therapeutic strategies based on angiogenesis attract great attention from fundamental and clinical research. Blocking oxygen and nutrition supply to tumor cells could inhibit the growth of tumor based on occlusion of blood vessels in tumor. Herein, we report a dual-responsive peptide-based nanoparticle, mimicking the laminin fibrillogenesis specifically and high-efficiently in tumor vessels, resulting in the blockage of tumor vessels and the growth inhibition of tumor. The laminin mimic peptide (LMMP) is designed with fibrillation sequence, pH-responsive sequence and targeting sequence. The LMMP in nanoformulation is delivered to the blood vessel in tumor, where the microenvironment (pH and microthrombus) enable LMMP to process laminin fibrillogenesis, constructing fibrous networks. The laminin-like fibrous networks capture red blood cells etc., forming occlusion specifically in tumor blood vessels for inhibiting the growth of tumor.
- Open Access
- 8 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (19) , eaaz4767
A biomimetic peptide recognizes and traps bacteria in vivo as human defensin-6
Using broad-spectrum antibiotics for microbial infection may cause flora disequilibrium, drug-resistance, etc., seriously threatening human health. Here, we design a human defensin-6 mimic peptide (HDMP) that inhibits bacterial invasion in vivo through mimicking the mechanisms of human defensin-6 with high efficiency and precision. The HDMP with ligand and self-assembling peptide sequence recognizes bacteria through ligand-receptor interactions and subsequently traps bacteria by an in situ adaptive self-assembly process and resulting nanofibrous networks; these trapped bacteria are unable to invade host cells. In four animal infection models, the infection rate was markedly decreased. Notably, administration of HDMP (5 mg/kg) nanoparticles increased the survival rate of mice with methicillin-resistant S. aureus bacteremia by as much as 100%, even more than that of vancomycin treatment (5 mg/kg, 83.3%)–treated group, the golden standard of antibiotics. This biomimetic peptide shows great potential as a precise and highly efficient antimicrobial agent.
- 8 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (19) , eaaz4767
Open AccessA biomimetic peptide recognizes and traps bacteria in vivo as human defensin-6
Using broad-spectrum antibiotics for microbial infection may cause flora disequilibrium, drug-resistance, etc., seriously threatening human health. Here, we design a human defensin-6 mimic peptide (HDMP) that inhibits bacterial invasion in vivo through mimicking the mechanisms of human defensin-6 with high efficiency and precision. The HDMP with ligand and self-assembling peptide sequence recognizes bacteria through ligand-receptor interactions and subsequently traps bacteria by an in situ adaptive self-assembly process and resulting nanofibrous networks; these trapped bacteria are unable to invade host cells. In four animal infection models, the infection rate was markedly decreased. Notably, administration of HDMP (5 mg/kg) nanoparticles increased the survival rate of mice with methicillin-resistant S. aureus bacteremia by as much as 100%, even more than that of vancomycin treatment (5 mg/kg, 83.3%)–treated group, the golden standard of antibiotics. This biomimetic peptide shows great potential as a precise and highly efficient antimicrobial agent.